海普瑞:H股公告2020-11-13
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深 圳 市 海 普 瑞 藥 業 集 團 股 份 有 限 公 司)
9989
RESVERLOGIX
Resverlogix Corp. Resverlogix RVX
Apabetalone – -2 (SGLT2)
(eGFR) (HbA1c) BETonMACE 3
Resverlogix
Apabetalone SGLT2
SGLT2 (p=0.05) Apabetalone
SGLT2 eGFR
(p<0.001) Apabetalone SGLT2
HbA1c
Apabetalone SGLT2 Resverlogix
2040
MACE Apabetalone SGLT2
CKD
eGFR HbA1c
BETonMACE CKD
CKD
Resverlogix Apabetalone SGLT2
1
eGFR CKD
eGFR CKD
CKD
CKD 700 CKD
HbA1c
HbA1c HbA1c II
(T2DM) HbA1c
HbA1c 4.0% 5.6% HbA1c
5.7% 6.4% HbA1c 6.5% T2DM
T2DM
HbA1c
SGLT2 T2DM
HbA1c T2DM HbA1c
7.0% SGLT2 HbA1c 7.0%
2013 FDA
T2DM
2024 250 Mordor Intelligence 2019
SGLT2
(ACS) MACE
RESVERLOGIX
Resverlogix 2000 8 17
RVX Resverlogix 38.50%
Resverlogix Apabetalone (RVX-208)
BET Apabetalone FDA
2
BET Apabetalone BET
(BD2) BET Apabetalone BD2
RVX-208 (Apabetalone)
RVX-208 (Apabetalone)
2020 11 12
3